Effect of edaravone on serum SP-A and arterial blood gas in patients with lobectomy

Objective: To discuss the effect of edaravone on serum pulmonary surfactant protein A (SP-A) and arterial blood gas (ABG) in patients with thoracoscopic lobectomy. Methods: 40 lung cancer patients with right side of lobectomy were randomly divided into control group (group C, 20 cases) and edaravone group (group E, 20 cases). Group E was treated edaravone (1 mg/kg) between induction and skin incision, dropping within 30 min; group C was treated with equivalent normal saline. The venous and arterial blood were collected in both groups immediately before incision (T0), after 1 h of one-lung ventilation 1 h (T1) and in 1 h after lungs ventilation (T2) for ABG analysis and measurement of serum SP-A level. Results After OLV, serum SP-A levels were significantly increased in both groups (P < 0.05); compared with group C, serum levels of SP-A were reduced (P < 0.05) and ABG was significantly improved in group E. Conclusion: Edaravone can reduce serum SP-A levels in patients with lobectomy and alleviate acute lung injury to a certain extent in surgery.